Extended distribution agreement enables customers to continuously improve their bioprocesses
Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.
Pall Corporation has extended a consumables distribution agreement with Kaneka Corporation. In addition to flagship Kaneka KanCapA Protein A chromatography sorbents, the Pall Biotech business unit now features the company’s next-generation Kaneka KanCapA 3G sorbent for the primary capture of monoclonal antibodies (mAbs) from clarified cell culture. The sorbents are available in off-the-shelf bulk format for use with large columns, such as Resolute AutoPak columns, and a range of pre-packed columns.
“Increasing demand for more targeted and personalized medicines is driving growth and development in the mAb manufacturing market. In combination with our industry-leading portfolio of downstream process equipment, Kaneka KanCapA 3G sorbent offers a complete solution to customers looking to make these products,” said Mario Philips, Vice President and General Manager at Pall Biotech. “Through the collaboration with the Kaneka team we are able to ensure consistency, quality and reliability with an industry-leading sorbent that enables customers to continuously improve their bioprocesses.”
The full Kaneka KanCapA line of products is based on a robust matrix that enables the high productivity affinity capture of mAbs and related biomolecules using a proprietary alkali stable rPrA ligand. Designed with a combination of proprietary recombinant ligand and a highly cross-linked cellulose base matrix, the new Kaneka KanCapA 3G sorbent exhibits enhanced binding capacity, an excellent elution profile, and advanced impurity removal properties when compared with other market sorbents.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.